89bio, Inc. Contracts & Agreements
55 Contracts & Agreements
- Business Finance (24 contracts)
- Business Operations (5)
- Human Resources (15)
- Intellectual Property (1)
- Real Estate (4)
- Uncategorized (6)
- Form of Pre-Funded Warrant (Filed With SEC on November 14, 2024)
- Underwriting Agreement, dated as of November 12, 2024, by and among 89bio, Inc., Goldman Sachs & Co. LLC, Leerink Partners LLC and Evercore Group L.L.C (Filed With SEC on November 14, 2024)
- Office Sublease by and between 89bio, Inc. and Sender, Inc., dated as of October 20, 2023 (Filed With SEC on November 7, 2024)
- Executive Employment Offer Letter, dated July 31, 2024, by and between the Company and Francis Sarena (Filed With SEC on November 7, 2024)
- Form of Warrant to Purchase Common Stock for K2 HealthVentures LLC (Filed With SEC on October 3, 2024)
- Collaboration Agreement, dated as of April 4, 2024, by and between the Company and BiBo Biopharma Engineering Co., Ltd (Filed With SEC on August 5, 2024)
- Description of Securities (Filed With SEC on March 1, 2024)
- Form of Pre-Funded Warrant (Filed With SEC on December 8, 2023)
- Underwriting Agreement, dated as of December 6, 2023, by and among 89bio, Inc., BofA Securities, Inc. and Leerink Partners LLC (Filed With SEC on December 8, 2023)
- 89bio, Inc. Underwriting Agreement (Filed With SEC on March 28, 2023)
- Amendment No. 1 to Sales Agreement, dated February 15, 2023, by and among 89bio, Inc., SVB Securities LLC and Cantor Fitzgerald & Co (Filed With SEC on February 16, 2023)
- Form of Warrant to Purchase Common Stock for K2 HealthVentures LLC (Filed With SEC on February 2, 2023)
- Loan and Security Agreement, dated as of January 4, 2023, among 89bio, Inc., 89bio Management, Inc., 89Bio Ltd., K2 HealthVentures LLC and Ankura Trust Company, LLC (Filed With SEC on January 6, 2023)
- Amendment to Office Lease, by and between 89bio, Inc. and King Family Irrevocable Trust, dated as of August 31, 2022 (Filed With SEC on November 10, 2022)
- Form of Pre-Funded Warrant (Filed With SEC on July 1, 2022)
- Form of Warrant (Filed With SEC on July 1, 2022)
- 89bio, Inc. Underwriting Agreement (Filed With SEC on July 1, 2022)
- Description of Securities (Filed With SEC on March 24, 2022)
- First Amendment to Office Lease, dated as of July 27, 2021, by and between King Family Irrevocable Trust and the Company (Filed With SEC on November 12, 2021)
- Third Amendment to Loan and Security Agreement, dated as of May 28, 2021, among Silicon Valley Bank, the Lenders party thereto, 89bio, Inc., 89bio Management, Inc. and 89Bio Ltd (Filed With SEC on June 4, 2021)
- Form of Warrant to Purchase Common Stock for Silicon Valley Bank (Filed With SEC on June 4, 2021)
- Second Amendment to Loan and Security Agreement, dated as of April 30, 2021, among Silicon Valley Bank, the Lenders party thereto, 89bio, Inc., 89bio Management, Inc. and 89bio Ltd (Filed With SEC on May 14, 2021)
- First Amendment to Loan and Security Agreement, dated as of March 30, 2021, among Silicon Valley Bank, the Lenders party thereto, 89bio, Inc., 89bio Management, Inc. and 89Bio Ltd (Filed With SEC on May 14, 2021)
- Description of Securities (Filed With SEC on March 25, 2021)
- Non-Employee Director Compensation Policy (Filed With SEC on November 13, 2020)
- Amended and Restated Executive Employment Agreement, dated July 28, 2020, by and between 89Bio Ltd. and Ram Waisbourd (Filed With SEC on September 14, 2020)
- Form of Underwriting Agreement (Filed With SEC on September 14, 2020)
- Form of Underwriting Agreement (Filed With SEC on July 6, 2020)
- Non-Employee Director Compensation Policy (Filed With SEC on May 13, 2020)
- Executive Employment Offer Letter, dated April 15, 2020, by and between 89bio, Inc. and Quoc Le-Nguyen (Filed With SEC on May 4, 2020)
- Executive Employment Offer Letter, dated April 15, 2020, by and between 89bio, Inc. and Hank Mansbach (Filed With SEC on May 4, 2020)
- Executive Employment Offer Letter, dated April 15, 2020, by and between 89bio, Inc. and Ryan Martins (Filed With SEC on May 4, 2020)
- Executive Employment Offer Letter, dated April 15, 2020, by and between 89bio, Inc. and Rohan Palekar (Filed With SEC on May 4, 2020)
- Loan and Security Agreement, dated as of April 7, 2020, among Silicon Valley Bank, the Lenders party thereto, 89bio, Inc., 89bio Management, Inc. and 89Bio Ltd (Filed With SEC on April 13, 2020)
- Form of Warrant to Purchase Common Stock for Silicon Valley Bank (Filed With SEC on April 13, 2020)
- Office Lease by and between 89bio, Inc. and King Family Irrevocable Trust, dated as of December 5, 2019 (Filed With SEC on March 18, 2020)
- Description of Securities (Filed With SEC on March 18, 2020)
- Specimen common stock certificate of the registrant (Filed With SEC on October 28, 2019)
- Form of Underwriting Agreement (Filed With SEC on October 28, 2019)
- Amended and Restated 2019 Equity Incentive Plan and forms of agreements thereunder (Filed With SEC on October 28, 2019)
- 2019 Employee Stock Purchase Plan (Filed With SEC on October 28, 2019)
- Non-Employee Director Compensation Policy (Filed With SEC on October 28, 2019)
- Director Offer Letter, dated July 1, 2018, by and between 89Bio Ltd. and Michael Hayden (Filed With SEC on October 11, 2019)
- Executive Employment Offer Letter, dated July 21, 2019, by and between 89Bio Ltd. and Ryan Martins (Filed With SEC on October 11, 2019)
- Executive Employment Offer Letter, dated February 28, 2019, by and between 89Bio Ltd. and Quoc Le-Nguyen (Filed With SEC on October 11, 2019)
- Executive Employment Offer Letter, dated November 20, 2018, by and between 89Bio Ltd. and Hank Mansbach (Filed With SEC on October 11, 2019)
- Executive Employment Agreement, dated April 23, 2018, by and between 89Bio Ltd. and Ram Waisbourd (Filed With SEC on October 11, 2019)
- Executive Employment Offer Letter, dated June 25, 2018, by and between 89Bio Ltd. and Rohan Palekar (Filed With SEC on October 11, 2019)
- Form of Indemnification Agreement for directors and executive officers, to be in effect upon completion of this offering (Filed With SEC on October 11, 2019)
- Investors Rights Agreement, dated as of September 17, 2019, by and among the registrant and certain of its shareholders (Filed With SEC on October 11, 2019)
- Contribution and Exchange Agreement, dated as of September 17, 2019, by and among 89Bio, Ltd., the registrant and its shareholders (Filed With SEC on October 11, 2019)
- Asset Transfer and License AgreementFGF21 by and among 89Bio Ltd., ratiopharm GmbH, Teva Branded Pharmaceutical Products R&D, Inc. and Teva Pharmaceutical Industries Ltd, dated as... (Filed With SEC on October 11, 2019)
- Reagent Supply and Technology Transfer Agreement by and between 89Bio Ltd. and Teva Biotech GmbH, dated as of April 16, 2018, as amended (Filed With SEC on October 11, 2019)
- Sublicense Agreement by and between 89Bio Ltd. and ratiopharm GmbH, dated as of April 16, 2018 (Filed With SEC on October 11, 2019)
- Master Services Agreement by and between 89Bio Ltd. and Biotechpharma UAB, dated as of May 7, 2018, as amended (Filed With SEC on October 11, 2019)
